3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
92
Fallopian Tube Neoplasms
25
Breast Neoplasms
21
Endometrial Neoplasms
19
Carcinoma, Ovarian Epithelial
12
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Neoplasms
6
Fanconi Anemia, Complementation Group D1
5
Uterine Cervical Neoplasms
4
Recurrence
4
Neoplasm Metastasis
4
Carcinoma, Renal Cell
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Peritoneal Neoplasms
2
Ovarian Diseases
2
Carcinosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Relapsed Ovarian Cancers Patients
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Platinum-sensitive Ovarian Cancer
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Interventions
Fulvestrant
3
cobimetinib
2
anlotinib
2
Bevacizumab
2
trametinib
1
selinexor
1
ribociclib
1
relacorilant
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
nintedanib
1
exemestane
1
enzalutamide
1
dabrafenib
1
atezolizumab
1
alectinib
1
abemaciclib
1
Watchful Waiting
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Trabectedin
1
Tamoxifen
1
STX-478
1
Pregnancy Tests
1
Pemetrexed
1
Metformin
1
Letrozole
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
olaparib
×
Gynecologic
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled